Edgewise Therapeutics, Inc.
EWTX
Rangering i aksjer
#3850
Edgewise Therapeutics, Inc. is a biopharmaceutical firm dedicated to developing... Edgewise Therapeutics, Inc. is a biopharmaceutical firm dedicated to developing small-molecule treatments for a range of musculoskeletal disorders. Its leading investigational drug, EDG-5506, is an orally administered compound specifically engineered to tackle the fundamental genetic causes of dystrophinopathies, including Duchenne and Becker muscular dystrophy. This candidate has successfully concluded its Phase 1 clinical trial. Beyond EDG-5506, Edgewise maintains a pipeline of precision medicine candidates designed to modulate key muscle proteins, thereby addressing various genetically defined muscle conditions. Established in 2017, the company is headquartered in Boulder, Colorado.
Aksjekurs
$39.70
Sist synkronisert: 2026-10-21
Markedsverdi
$4.27B
Endring (1 dag)
-0.12%
Endring (1 år)
166.64%
Land
US
Handel Edgewise Therapeutics, Inc. (EWTX)
Kategori
Healthcare
Aksjeprishistorikk for Edgewise Therapeutics, Inc. (EWTX)
Høyeste sluttskurs: $38.97 den 2026-10-01
Laveste sluttskurs: $32.43 den 2021-03-01
Laveste sluttskurs: $32.43 den 2021-03-01
Aksjeprishistorikk for Edgewise Therapeutics, Inc. fra 2021 til 2026
Årlig aksjeprisytelse
| År | Ytelse |
|---|---|
| 2026 (TTM) | 38.00% |
| 2025 | -20.97% |
| 2024 | 268.96% |
| 2023 | -1.80% |
| 2022 | -51.10% |
| 2021 | 0.00% |
Aksjepris for lignende selskaper eller konkurrenter
| Selskap | Aksjepris | Endring 1år% | Land |
|---|---|---|---|
| $527.18 | 23.62% |
US
|
|
| $251.29 | 835.90% |
US
|
|
| $137.44 | -4.05% |
AU
|
|
| $890.85 | 9.42% |
NL
|
|
| $752.87 | 7.01% |
CH
|
